natgillin/translations-raw huggingface dataset:
EU/1/13/880/001 28 film-coated tablets EU/1/13/880/002 30 film-coated tablets EU/1/13/880/003 42 film-coated tablets EU/1/13/880/004 50 film-coated tablets EU/1/13/880/005 56 film-coated tablets EU/1/13/880/006 98 film-coated tablets EU/1/13/880/007 100 film-coated tablets EU/1/13/880/008 112 film-coated tablets EU/1/13/880/014 14 film-coated tablets 
EU/1/13/880/001 28 filmom obloženih tableta EU/1/13/880/002 30 filmom obloženih tableta EU/1/13/880/003 42 filmom obloženih tableta EU/1/13/880/004 50 filmom obloženih tableta EU/1/13/880/005 56 filmom obloženih tableta EU/1/13/880/006 98 filmom obloženih tableta EU/1/13/880/007 100 filmom obloženih tableta EU/1/13/880/008 112 filmom obloženih tableta EU/1/13/880/014 14 filmom obloženih tableta
Memantine Accord 10 mg film-coated tablets memantine hydrochloride 
Memantin Accord 10 mg filmom obložene tablete memantinklorid
Each film-coated tablet contains 15 mg memantine hydrochloride equivalent to 12.46 mg memantine. 
Svaka filmom obložena tableta sadrži 15 mg memantinklorida, što odgovara 12,46 mg memantina.
Memantine Accord 20 mg film-coated tablets memantine hydrochloride 
Memantin Accord 20 mg filmom obložene tablete memantinklorid
Immune systeme disorders 
Poremećaji probavnog sustava
Pale red to grey-red, oblong, scored, coated tablet, debossed with “MT” divided by the score on one side and "20" divided by the score on the other side. 
Blijedocrvena do sivo-crvena, duguljasta, obložena tableta, s razdjelnom crtom utisnutom između oznake “MT” na jednoj strani i razdjelnom crtom utisnutom između oznake “20” na drugoj strani.
White, oblong, coated and scored tablet, debossed with “MT” divided by the score on one side and "10" divided by the score on the other side. 
Bijela, duguljasta, obložena tableta, s razdjelnom crtom između utisnute oznake “MT” na jednoj strani i razdjelnom crtom između utisnute oznake “10” na drugoj strani.
The 10 mg film-coated tablets are white, oblong, coated and scored tablets, debossed with "MT" divided by the score on one side and "10" divided by the score on the other side. 
Filmom obložene tablete od 10 mg su bijele, duguljaste, obložene tablete, s razdjelnom crtom između utisnute oznake “MT” na jednoj strani i razdjelnom crtom između utisnute oznake “10” na drugoj strani.
The 20 mg film-coated tablets are pale red to grey-red, oblong, scored, coated tablets, debossed with "MT" divided by the score on one side and "20" divided by the score on the other side. 
Filmom obložene tablete od 20 mg su blijedocrvene do sivo-crvene, duguljaste, obložene tablete, s razdjelnom crtom između utisnute oznake ‘MT' na jednoj strani i razdjelnom oznakom između utisnute oznake ‘20' na drugoj strani.
Film-coated tablets. 
14 filmom obloženih tableta.
EU/1/13/880/020 14 x 1 film-coated tablets EU/1/13/880/021 28 x 1 film-coated tablets EU/1/13/880/022 56 x 1 film-coated tablets EU/1/13/880/023 98 x 1 film-coated tablets 
EU/1/13/880/020 14 x 1 filmom obložena tableta EU/1/13/880/021 28 x 1 filmom obložena tableta EU/1/13/880/022 56 x 1 filmom obložena tableta EU/1/13/880/023 98 x 1 filmom obložena tableta
EU/1/13/880/016 14 x 1 film-coated tablets EU/1/13/880/017 28 x 1 film-coated tablets EU/1/13/880/018 56 x 1film-coated tablets EU/1/13/880/019 98 x 1film-coated tablets 
EU/1/13/880/016 14 x 1 filmom obložena tableta EU/1/13/880/017 28 x 1 filmom obložena tableta EU/1/13/880/018 56 x 1 filmom obložena tableta EU/1/13/880/019 98 x 1 filmom obložena tableta
Memantine Accord 15 mg film-coated tablets are presented as orange to grey-orange, oblong, coated tablet, debossed with “MT” on one side and “15” on the other side. 
Memantin Accord 15 mg filmom obložene tablete su narančaste do sivo-narančaste, duguljaste, obložene tablete, s utisnutom oznakom ‘MT' na jednoj strani i ‘15' na drugoj strani.
Each film-coated tablet contains 20 mg memantine hydrochloride equivalent to 16.62 mg memantine. 
Svaka filmom obložena tableta sadrži 20 mg memantinklorida, što odgovara 16,62 mg memantina.
Each film-coated tablet contains 10 mg of memantine hydrochloride equivalent to 8.31 mg memantine - The other ingredients are lactose monohydrate, microcrystalline cellulose, colloidal anhydrous silica, crospovidone, magnesium stearate, all in the tablet core; hypromellose, polysorbate 80, macrogol 400, titanium dioxide (E 171), all in the tablet coating 
Pomoćne tvari su: laktoza hidrat, mikrokristalična celuloza, koloidni bezvodni silicijev dioksid krospovidon i magnezijev stearat, sve u jezgri tablete; te hipromeloza, polisorbat 80, makrogol 400 i titanijev dioksid (E171), sve u ovojnici tablete.
Memantine Accord 5 mg film-coated tablets are presented as white, oblong, coated tablet, debossed with “MT” on one side and “5” on the other side. 
Memantin Accord 5 mg filmom obložene tablete su bijele, duguljaste, obložene tablete, s utisnutom oznakom ‘MT' na jednoj strani i ‘5' na drugoj strani.
Iron oxide yellow and red (E 172) 
Ovojnica tablete hipromeloza polisorbat 80 makrogol 400 titanijev dioksid (E 171) željezov oksid, žuti i crveni (E 172)
Memantine Accord 20 mg film-coated tablets are presented as pale red to greyred, oblong, coated and scored tablet, debossed with “MT” divided by the score on one side and “20” divided by the score on the other side. 
Memantin Accord 20 mg filmom obložene tablete su blijedocrvene do sivo-crvene, duguljaste, obložene tablete, s razdjelnom crtom između utisnute oznake ‘MT' na jednoj strani i razdjelnom oznakom između utisnute oznake ‘20' na drugoj strani.
Memantine Accord 10 mg film-coated tablets are presented as white, oblong, coated and scored tablet, debossed with “MT” divided by the score on one side and “10” divided by the score on the other side. 
Memantin Accord 10 mg filmom obložene tablete su bijele, duguljaste, filmom obložene tablete, s razdjelnom crtom između utisnute oznake “MT” na jednoj strani i razdjelnom crtom između utisnute oznake “10” na drugoj strani.
The 15 mg film-coated tablets are orange to grey-orange, oblong, coated tablets debossedwith "MT" on one side and "15" on the other side. 
Filmom obložene tablete od 15 mg su narančaste do sivo-narančaste, duguljaste, obložene tablete, s utisnutom oznakom ‘MT' na jednoj strani i ‘15' na drugoj strani.
Tablet cores for 5/10/15/20 mg film-coated tablets Lactose monohydrate 
Jezgre tableta za 5/10/15/20 mg filmom obložene tablete laktoza hidrat celuloza, mikrokristalična silicijev dioksid, koloidni, bezvodni krospovidon magnezijev stearat
Memantine Accord with food and drink 
Uzimanje hrane i pića s lijekom Memantin Accord
EU/1/13/880/009 28 fim-coated tablets EU/1/13/880/010 42 fim-coated tablets EU/1/13/880/011 56 fim-coated tablets EU/1/13/880/012 98 fim-coated tablets EU/1/13/880/015 14 fim-coated tablets 
EU/1/13/880/009 28 filmom obloženih tableta EU/1/13/880/010 42 filmom obloženih tableta EU/1/13/880/011 56 filmom obloženih tableta EU/1/13/880/012 98 filmom obloženih tableta EU/1/13/880/015 14 filmom obloženih tableta
Week 2 (day 8-14): The patient should take one 10 mg film-coated tablet per day (white, scored) for 7 days. 
2. tjedan (8. - 14. dan): Bolesnik treba uzimati jednu filmom obloženu tabletu od 10 mg dnevno, tijekom 7 dana.
week 1 
5. DRUGO
Memantine Accord film-coated tablets are presented as white, oblong, coated and scored tablet,debossed with "MT" divided by the score on one side and “10” divided by the score on the other side. 
Memantin Accord filmom obložene tablete su bijele, duguljaste, obložene tablete, s razdjelnom crtom između utisnute oznake “MT” na jednoj strani te s razdjelnom crtom između utisnute oznake “10” na drugoj strani.
Memantine Accord film-coated tablets are presented as pale red to greyred, oblong, coated and scored tablet, debossed with "MT" divided by the score on one side and “20” divided by the score on the other side. 
Memantin Accord filmom obložene tablete su blijedocrvene do sivo-crvene, duguljaste, obložene tablete, s razdjelnom crtom između utisnute oznake ‘MT' na jednoj strani te s razdjelnom crtom između utisnute oznake ‘20' na drugoj strani.
Excipients 
Cipar
Week 4 (day 22-28): The patient should take one 20 mg film-coated tablet per day (pale red to grey-red, scored) for 7 days. 
Bolesnik treba uzimati jednu filmom obloženu tabletu od 20 mg (blijedocrvenu do sivo-crvenu, s razdjelnom crtom) dnevno tijekom 7 dana.
The patient should take one 10 mg film-coated tablet per day for 7 days. 
Bolesnik treba uzimati jednu filmom obloženu tabletu od 10 mg (bijelu, s razdjelnom crtom) dnevno tijekom 7 dana.
This summary was last updated in December 2014. 
Sažetak je posljednji put ažuriran u prosincu 2014.
Protection prevents mortality and reduces infection and disease. 
Imunizacija sprječava smrtnost i smanjuje infekciju i bolest.
Vaccines work by ‘teaching' the immune system (the body's natural defences) how to defend itself against a disease. 
Cjepiva djeluju "učeći" imunosni sustav (prirodnu obranu tijela) kako da se brani od bolesti.
Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use. 
Cilj mu je objasniti kako procjena, koju Odbor za veterinarsko- medicinske proizvode (CVMP) provodi na temelju zaprimljene dokumentacije, dovodi do preporuka o uvjetima korištenja.
The vaccine is given to pigs from seven weeks of age as a single injection into the muscle. 
Cjepivo se primjenjuje u svinja u dobi od 7 tjedana starosti kao jedna injekcija u mišić.
This disease causes fever, skin lesions, convulsions and often leads to death of the animals. 
Ova bolest uzrokuje vrućicu, kožne lezije, konvulzije, te često rezultira smrću životinje.
The European Commission granted a marketing authorisation valid throughout the European Union, for Suvaxyn CSF Marker on 10/02/2015. 
Europska komisija izdala je odobrenje za stavljanje u promet koje je na snazi u Europskoj uniji za za VMP Suvaxyn CSF Marker dana 10/02/2015.
The purpose of these studies was to establish how long it took for pigs to be fully protected and the length of time protection lasts against CSFV. 
Svrha ovih ispitivanja bila je utvrditi koliko dugo je potrebno svinjama da postignu potpunu zaštitu te duljinu trajanja zaštite protiv VKSK-a.
Protection starts two weeks after vaccination and lasts for at least six months. 
Imunizacija započinje dva tjedna nakon cijepljenja i traje najmanje šest mjeseci.
The main measure of effectiveness was development of antibodies against E2 protein 14 days after vaccination. 
Glavna mjera djelotvornosti bio je razvoj protutjela protiv proteina E2 14 dana nakon cijepljenja.
The effectiveness of the vaccine was first studied in a number of laboratory studies in pigs. 
Djelotvornost cjepiva po prvi puta je ispitana u nizu laboratorijskih ispitivanja.
This will help to protect against the disease. 
Ovo pomaže u imunizaciji protiv bolesti.
The vaccine is available as a lyophilisate (freeze dried powder) and solvent for injection. 
Cjepivo je dostupno kao liofizat (zamrznuti suhi prašak) i otapalo za injekciju.
In the future, if the animals are exposed to CSFV, their immune system will be triggered by the virus and be able to respond more quickly. 
U buduće, ako se životinje izlože VKSK-u, virus aktivira njihov imunosni sustav i mogu brže odgovoriti.
Classical swine fever vaccine (live recombinant) 
Cjepivo protiv klasične svinjske kuge (živo rekombinirano)
In case of accidental self-injection, medical advice should be sought immediately and the package leaflet or label shown to the doctor. 
Pri slučajnom samoinjiciranju potrebno je odmah potražiti liječnički savjet uz predočenje upute ili etikete liječniku.
When the vaccine is given to a healthy pig, the animal's immune system recognises the vaccine virus as ‘foreign' and makes antibodies against it. 
Nakon što se cjepivo primjeni u zdravih svinja, imunosni sustav životinje prepoznaje virus iz cjepiva kao "strano tijelo" i proizvodi protutijela protiv njega.
The laboratory studies showed that the vaccine had its full effect against CSFV by two weeks. 
Laboratorijskim ispitivanjima utvrđeno je da cjepivo ima potpuno djelovanje protiv VKSK-a do drugog tjedna.
The effectiveness of Suvaxyn CSF Marker was further investigated in a small scale study with 30 eight-week-old piglets. 
Nadalje djelotvornost VMP-a Suvaxyn CSF Marker je istražena u ispitivanju malih razmjera u 30 osam tjedana starih praščića.
This is because if given to pregnant sows it does not prevent them from passing CSFV infection to their offspring but can hide signs of infection in the piglets, allowing them to spread the disease. 
Razlog tomu je što ako se primjeni u gravidnih krmača, cjepivo ne sprječava širenje infekcije VKSK-om na potomstvo, no može prikriti znakove infekcije u prašćića, čime im omogućuje širenje bolesti.
The withdrawal period is the time allowed after administration of the medicine and before the animal can be slaughtered and the meat used for human consumption or eggs or milk used for human consumption. 
Karencije je razdoblje koje treba proći od primjene VMP-a do klanja životinja i konzumacije mesa u ljudskoj prehrani ili jaja ili mlijeka u ljudskoj prehrani.
As CSF is a notifiable disease, it is not possible to conduct standard field studies. 
Budući da VKSK-a podliježe obvezi prijavljivanja, nije moguće provesti standardna terenska ispitivanja.
There are no known side effects with Suvaxyn CSF Marker when it is used according to the approved indication of the product information. 
Nema poznatih nuspojava s VMP-om Suvaxyn CSF Marker kada se koristi u skladu s odobrenim indikacijama informacija o proizvodu.
The CVMP concluded that the benefits of Suvaxyn CSF Marker exceed the risks for the approved indication and recommended that Suvaxyn CSF Marker be given a marketing authorisation. 
CVMP je zaključio da VMP-a Suvaxyn CSF Marker nadmašuju rizike za odobrene indikacije i preporučio je da se VMP-u Suvaxyn CSF Marker izda odobrenje za stavljanje VMP-a u promet.
Protection lasted at least six months after vaccination. 
Imunizacija je trajala najmanje šest tjedana nakon cijepljenja.
Twenty piglets were given Suvaxyn CSF Marker and 10 piglets were given a placebo (dummy) injection. 
Dvadeset praščića primilo je Suvaxyn CSF Marker, a 10 praščića primilo je placebo (lažnu) injekciju.
The benefit-risk balance may be found in the scientific discussion module of this EPAR. 
Omjer koristi i rizika dostupan je i u modulu znanstvene rasprave ovog EPAR-a.
Suvaxyn CSF Marker is used to protect pigs against outbreaks of classical swine fever, a very severe and highly contagious viral disease of both wild and domestic pigs. 
Suvaxyn CSF Marker koristi se za imunizaciju svinja protiv izbijanja klasične svinjske kuge, vrlo ozbiljne i vrlo zarazne virusne bolesti divljih i domaćih svinja.
The vaccine virus in Suvaxyn CSF Marker has been modified so that it will produce the E2 protein, which is part of the outer coat of the closely related virus CSFV, which it provides protection against. 
Virus u cjepivu Suvaxyn CSF Marker modificiran je tako da stvara protein E2, koji je sastavni dio vanjskog omotača usko povezanog virusa VKSK-a, protiv kojeg pruža imunizaciju.
The vaccine has potential marker properties which may allow detection of pigs infected with field CSFV as distinct from Suvaxyn CSF Marker vaccinated pigs, in accordance with the DIVA principle (differentiation of infection from vaccination). 
Cjepivo ima karakteristike potencijalnoga markera koji može omogućiti otkrivanje svinja zaraženih terenskim VKVS-om te ih razlikovati od svinja cijepljenih Suvaxyn CSF Marker cjepivom u skladu s DIVA načelom (diferencijacija infekcije od cjepiva).
Suvaxyn CSF Marker should not be used to vaccinate sows. 
Suvaxyn CSF Marker ne smije se koristiti za cijepljenje krmača.
Suvaxyn CSF Marker is a vaccine containing bovine viral diarrhoea virus, which can infect pigs but does not normally cause disease in them. 
Suvaxyn CSF Marker je cjepivo koje sadrži virus goveđe virusne dijareje, koja može zaraziti svinje, no normalno ne uzrokuje bolest u svinja.
The field study showed that vaccination with Suvaxyn CSF Marker resulted in 19 out of 20 piglets developing antibodies against E2 protein. 
Terenskim je ispitivanjem utvrđeno da je cijepljenje VMP-om Suvaxyn CSF Marker rezultiralo razvojem protutijela protiv proteina E2 u 19 od 20 praščića.
Suvaxyn CSF Marker is a recombinant veterinary vaccine that contains live bovine viral diarrhoea virus (BVDV) which has been modified to replace the envelope (E2) gene of BVDV with the corresponding gene of classical swine fever virus (CSFV). 
Suvaxyn CSF Marker ije rekombinantno veterinarsko cjepivo koje sadrži živi virus goveđe virusne dijareje (BDV) koji je rekombiniran deletiranim E2 genom kako bi odgovarao genu klasičnog virusa svinjske kuge (VKSK).
The withdrawal period for Suvaxyn CSF Marker for pigs is zero days. 
Razdoblje karencije za Coxevac za meso i mlijeko iznosi nula dana.
Other information about Suvaxyn CSF Marker: 
Ostale informacije o VMP-u Suvaxyn CSF Marker:
What is the risk associated with Suvaxyn CSF Marker? 
Koji su rizici povezani s VMP-om Suvaxyn CSF Marker?
Why has Suvaxyn CSF Marker been approved? 
Zašto je Suvaxyn CSF Marker odobren?
What is Suvaxyn CSF Marker? 
Što je Suvaxyn CSF Marker?
What is Suvaxyn CSF Marker used for? 
Za što se Suvaxyn CSF Marker koristi?
What benefit has Suvaxyn CSF Marker shown during the studies? 
Koje su koristi VMP-a Suvaxyn CSF Markerutvrđene u ispitivanjima?
How has Suvaxyn CSF Marker been studied? 
Kako je Suvaxyn CSF Marker ispitivan?
How does Suvaxyn CSF Marker work? 
Kako djeluje Suvaxyn CSF Marker?
DuoPlavin must not be used during the last three months of pregnancy. 
Lijek DuoPlavin ne smije se uzimati tijekom posljednja tri mjeseca trudnoće.
Acetylsalicylic acid has been available for over 100 years. 
Acetilsalicilatna kiselina dostupna je već više od 100 godina.
The full EPAR for DuoPlavin can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Cjeloviti EPAR za lijek DuoPlavin nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The European Commission granted a marketing authorisation valid throughout the EU for DuoPlavin on 15 March 2010. 
Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek DuoPlavin na snazi u Europskoj uniji od 15. ožujka 2010.
It also presented the results of 3 previous studies involving over 61,000 patients with unstable angina or who had had a heart attack. 
Tvrtka je predstavila i rezultate triju prethodnih ispitivanja koja su uključivala više od 61 000 bolesnika s nestabilnom anginom ili bolesnika koji su imali srčani udar.
It can be used in the following groups of patients who have a condition known as ‘acute coronary syndrome': 
Može se primjenjivati u sljedećim skupinama bolesnika koji boluju od bolesti poznate pod nazivom „akutni koronarni sindrom”:
It is available as tablets containing 75 mg clopidogrel, either with 75 mg or 100 mg acetylsalicylic acid. 
Dostupan je u obliku tableta koje sadrže 75 mg klopidogrela i 75 ili 100 mg acetilsalicilatne kiseline.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for DuoPlavin. 
Objašnjava kako je Odbor za lijekove za humanu uporabu (CHMP) ocijenio lijek da bi donio svoje mišljenje u korist izdavanja odobrenja za stavljanje lijeka u promet te preporuke o uvjetima za primjenu lijeka DuoPlavin.
For more information about treatment with DuoPlavin, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Više informacija o terapiji lijekom DuoPlavin pročitajte u uputi o lijeku (također dio EPAR-a), ili se obratite svom liječniku ili ljekarniku.
Clopidogrel has been authorised since 1998 for reducing platelet aggregation, and is often used in combination with acetylsalicylic acid. 
Klopidogrel je odobren od 1998. kao lijek za smanjenje agregacije trombocita i često se koristi u kombinaciji s acetilsalicilatnom kiselinom.
DuoPlavin clopidogrel / acetylsalicylic acid 
DuoPlavin klopidogrel/acetilsalicilatna kiselina
This document is a summary of the European Public Assessment Report (EPAR) for DuoPlavin. 
Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku DuoPlavin.
Because the two active substances have been used together for a number of years, the company presented the results of studies showing that the active substances in DuoPlavin are absorbed in the body in the same way when taken in a single tablet as when the two medicines are taken separately. 
S obzirom na to da se te dvije djelatne tvari zajedno koriste već niz godina, tvrtka je predstavila rezultate ispitivanja koji pokazuju da se djelatne tvari u lijeku DuoPlavin apsorbiraju u tijelo na isti način kao i kada se uzimaju kao pojedinačna tableta kada se ta dva lijeka uzimaju zasebno.
The Committee therefore decided that DuoPlavin's benefits are greater than its risks and recommended that it be given marketing authorisation. 
Odbor je stoga odlučio da koristi od lijeka DuoPlavin nadmašuju s njim povezane rizike te je preporučio izdavanje odobrenja za stavljanje lijeka u promet.
This means that they help to prevent blood cells called platelets from sticking together and forming clots, thus helping to prevent another heart attack. 
To znači da pomažu u sprečavanju sljepljivanja krvnih stanica koje se nazivaju trombociti i stvaranja krvnih ugrušaka, pomažući tako u sprečavanju pojave novog srčanog udara.
This stops the platelets becoming ‘sticky', reducing the risk of a blood clot forming. 
Time se sprečava da trombociti postanu „ljepljivi”, što smanjuje rizik od stvaranja krvnih ugrušaka.
DuoPlavin is a medicine that contains two active substances, clopidogrel and acetylsalicylic acid (also known as aspirin). 
DuoPlavin je lijek koji sadrži dvije djelatne tvari, klopidogrel i acetilsalicilatnu kiselinu (također poznatu kao aspirin).
The combination of the two active substances has an additive effect, reducing the risk of blood clots forming, more than either medicine alone. 
Kombinacija ovih dviju djelatnih tvari ima zbrojni učinak tako što smanjuje rizik od stvaranja krvnih ugrušaka u većoj mjeri nego ti lijekovi pojedinačno.
• patients who have ‘unstable angina' (a severe type of chest pain) or who have had a heart attack with no ‘ST-segment elevation' (an abnormal reading on the ECG or electrocardiogram), including those who are having a stent (a short tube) inserted into an artery to prevent it from closing up; 
• u bolesnika koji imaju „nestabilnu anginu” (teži oblik boli u prsima) ili u bolesnika koji su imali srčani udar bez „elevacije ST-segmenta” (abnormalan nalaz elektrokardiograma ili EKG-a), uključujući u bolesnika koji imaju ugrađen stent (kratku cijev) u arteriji radi sprečavanja njezina zatvaranja;
The most common side effects with DuoPlavin (seen in between 1 and 10 patients in 100) are haematoma (a collection of blood under the skin), epistaxis (nosebleeds), gastrointestinal haemorrhage (bleeding in the stomach or gut), diarrhoea, abdominal pain (stomach ache), dyspepsia (heartburn), bruising, and bleeding where the skin is punctured. 
Najčešće su nuspojave lijeka DuoPlavin (zabilježene u između 1 i 10 na 100 bolesnika) hematomi (nakupljanje krvi pod kožom), epistaksa (krvarenje iz nosa), gastrointestinalno krvarenje (krvarenje u želucu ili crijevima) proljev, abdominalna bol (bol u trbuhu), dispepsija (žgaravica), pojava modrica i krvarenje na mjestu uboda na koži.
What is the risk associated with DuoPlavin? 
Koji su rizici povezani s lijekom DuoPlavin?
• patients being treated for heart attack with ST-segment elevation, when the doctor thinks that they would benefit from thrombolytic treatment (treatment to dissolve blood clots). 
• u bolesnika koji primaju terapiju za srčani udar s „elevacijom ST-segmenta” u slučaju kada liječnik smatra da će im koristiti trombolitička terapija (terapija za otapanje krvnih ugrušaka).
Other information about DuoPlavin: 
Ostale informacije o lijeku DuoPlavin